CASP3 and sarcoma: At 5 h, no significant trend of increased serum caspase 3/7 was observed in the specific tumour types; the median per cent change from baseline caspase 3/7 levels was 3% for CRC, 12% for NSCLC and 1% for sarcoma patients (Figure 3A and Table 2).